Organisation paid for research Program year 2024 Source: CMS Open Payments

Centex Studies, Inc

Neither a doctor nor a teaching hospital

Research payments

$4,803,088

286 payments

Through program year 2024, Centex Studies, Inc is reported as receiving $4,803,088 in research payments, across 286 payments.

By program year

6 rows
Year Kind Amount Payments
2024 Research $268 1
2023 Research $349,660 6
2022 Research $896,094 13
2021 Research $3,415,156 151
2020 Research $57,274 46
2019 Research $84,637 69

Breakdown

Who paid Research payments · program years 2019–2024
  1. AstraZeneca Pharmaceuticals LP $4,642,322 40 payments
  2. AstraZeneca UK Limited $76,796 2 payments
  3. Novo Nordisk AS $62,850 236 payments
  4. Hikma Pharmaceuticals USA $10,348 1 payment
  5. Novartis Pharmaceuticals Corporation $4,486 3 payments
  6. Celgene Corporation $3,628 2 payments
  7. AstraZeneca AB $2,500 1 payment
  8. E.R. Squibb & Sons, L.L.C. $159 1 payment
Studies the money was for Research payments · program years 2019–2024
  1. A Phase III Randomized Double-blind Placebo-controlled Multicenter Study in Adults to Determine the Safety Efficacy and Immunogenicity of AZD1222 a Non-replicating ChAdOx1 Vector Vaccine for the Prevention of COVID-19 $4,277,593 12 payments
  2. Phase 1, Randomized, Open label, Three-arm, Single Dose, Parallel Group Study to Compare AZD7442 (AZD8895 and AZD1061) Pharmacokinetic Exposure Following Intramuscular Administration as a Co-formulation versus Administration from Two Separate Vials of the Individual Monoclonal Antibodies in Adult Healthy Participants $208,877 1 payment
  3. A Randomized Double-blind Placebo-controlled Study of the Safety Tolerability Pharmacokinetics and Pharmacodynamics of Multiple Ascending Doses of MEDI1341 in Subjects with Parkinsons Disease $76,796 2 payments
  4. Study to Assess the Efficacy and Safety of PT010 Relative to PT003 and PT009 in Subjects With Moderate to Very Severe COPD (Ethos) $48,600 2 payments
  5. Nn9535-4506 $46,717 87 payments
  6. A Randomized Double Blind Double Dummy Parallel Group Multicenter 24 to 52 Week Variable Length Study to Assess the Efficacy and Safety of Budesonide Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler $27,620 8 payments
  7. An Open label Long term Extension Study of Brazikumab in Participants with Moderately to Severely Active Crohns Disease $25,821 3 payments
  8. A Randomized Double Blind Double Dummy Parallel Group Multicenter 24 to 52 Week Variable Length Study to Assess the Efficacy and Safety of Budesonide Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler MDI Relative to Budesonide and Formoterol Fumarate MDI and Symbicort pMDI in Adult and Adolescent Participants with Inadequately Controlled Asthma $18,335 1 payment
  9. A Multicentre Randomized Double Blind Placebo Controlled Parallel Group Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Adults and Adolescents with Severe Uncontrolled Asthma $12,645 6 payments
  10. A Randomized Double-Blind Parallel Group Multi-Center 24-Week Study Comparing the Efficacy and Safety of Three Doses of PT001 to Placebo and Open-label Spiriva Respimat in Subjects With Persistent Asthma $11,751 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2024

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record